ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products is medical classification list by Centers for Medicare and Medicaid Services (CMS).

ICD-10-PCS code range (XW0), contains ICD-10-PCS codes for Cardiovascular System, New Technology, Anatomical Regions, Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Subscribe to Codify and get the code details in a flash.

PCS Tables

XW0

X New Technology
W Anatomical Regions
0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Body Part Approach Device / Substance / Technology Qualifier
Character 4 Character 5 Character 6 Character 7
Body System (Character 4)
0 Skin
Approach (Character 5)
X External
Substance (Character 6)
2 Bromelain-enriched Proteolytic Enzyme
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
9 Satralizumab-mwge
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Other New Technology Monoclonal Antibody
K Leronlimab Monoclonal Antibody
S COVID-19 Vaccine Dose 1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
X External
Substance (Character 6)
2 Bromelain-enriched Proteolytic Enzyme
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
2 Muscle
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
S COVID-19 Vaccine Dose 1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
0 Brexanolone
2 Nerinitide
3 Durvalumab Antineoplastic
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
5 Narsoplimab Monoclonal Antibody
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
6 Lefamulin Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
6 Terlipressin
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Coagulation Factor Xa, Inactivated
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Trilaciclib
8 Lurbinectedin
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
9 Defibrotide Sodium Anticoagulant
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
9 Ceftolozane/Tazobactam Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Bezlotoxumab Monoclonal Antibody
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Cefiderocol Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Ciltacabtagene Autoleucel
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Cytarabine and Daunorubicin Liposome Antineoplastic
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Omadacycline Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Amivantamab Monoclonal Antibody
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
C Eculizumab
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
D Atezolizumab Antineoplastic
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
E Remdesivir Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
E Etesevimab Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Bamlanivimab Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Plazomicin Anti-infective
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Sarilumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G REGN-COV2 Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Synthetic Human Angiotensin II
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Tocilizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Other New Technology Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Axicabtagene Ciloleucel Immunotherapy
J Tisagenlecleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Fosfomycin Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Idecabtagene Vicleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
L CD24Fc Immunomodulator
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
L Lifileucel Immunotherapy
M Brexucabtagene Autoleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
N Meropenem-vaborbactam Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
N Lisocabtagene Maraleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
0 Brexanolone
2 Nerinitide
3 Durvalumab Antineoplastic
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
5 Narsoplimab Monoclonal Antibody
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
6 Lefamulin Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
6 Terlipressin
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Coagulation Factor Xa, Inactivated
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Trilaciclib
8 Lurbinectedin
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
9 Defibrotide Sodium Anticoagulant
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
9 Ceftolozane/Tazobactam Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Bezlotoxumab Monoclonal Antibody
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Cefiderocol Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Ciltacabtagene Autoleucel
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Cytarabine and Daunorubicin Liposome Antineoplastic
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Omadacycline Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
B Amivantamab Monoclonal Antibody
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
C Eculizumab
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
D Atezolizumab Antineoplastic
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
E Remdesivir Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
E Etesevimab Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
F Bamlanivimab Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Plazomicin Anti-infective
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Sarilumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G REGN-COV2 Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Synthetic Human Angiotensin II
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Tocilizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Other New Technology Monoclonal Antibody
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
H Axicabtagene Ciloleucel Immunotherapy
J Tisagenlecleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Fosfomycin Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Idecabtagene Vicleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
L CD24Fc Immunomodulator
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
L Lifileucel Immunotherapy
M Brexucabtagene Autoleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
N Meropenem-vaborbactam Anti-infective
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
N Lisocabtagene Maraleucel Immunotherapy
Qualifier (Character 7)
7 New Technology Group 7
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
9 Nose
Approach (Character 5)
7 Via Natural or Artificial Opening
Substance (Character 6)
M Esketamine Hydrochloride
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
6 Lefamulin Anti-infective
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
8 Uridine Triacetate
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
F Other New Technology Therapeutic Substance
J Apalutamide Antineoplastic
L Erdafitinib Antineoplastic
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
M Baricitinib
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
R Venetoclax Antineoplastic
T Ruxolitinib
V Gilteritinib Antineoplastic
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
G Upper GI
H Lower GI
Approach (Character 5)
7 Via Natural or Artificial Opening
Substance (Character 6)
M Baricitinib
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
G Upper GI
H Lower GI
Approach (Character 5)
8 Via Natural or Artificial Opening Endoscopic
Substance (Character 6)
8 Mineral-based Topical Hemostatic Agent
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
Q Cranial Cavity and Brain
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
1 Eladocagene exuparvovec
Qualifier (Character 7)
6 New Technology Group 6
Body System (Character 4)
V Bones
Approach (Character 5)
0 Open
Substance (Character 6)
P Antibiotic-eluting Bone Void Filler
Qualifier (Character 7)
7 New Technology Group 7

December 31, 1969
Don8217t send another RHC claim until you8217ve reviewed these key changes for 2022. A Rural Health Clinic RHC is a clinic located in a rural underserved area with a shortage of primary care providers... [ Read More ]
December 31, 1969
New Work Plan item bodes ill for hospices. Hospices should get ready to defend their industrys reputation all over again. Why The HHS Office of Inspector General OIG plans to conduct a nationwide revi... [ Read More ]
December 31, 1969
The recently enacted No Surprises Act protects against most surprise billing but not ground ambulances. The No Surprises Act NSA which went into effect on Jan. 1 2022 protects people covered under gr... [ Read More ]
December 31, 1969
Mobile crisis intervention services deliver fast appropriate care to individuals in crisis and help to avoid unnecessary costly ER visits and hospitalizations. In an effort to expand behavioral health... [ Read More ]
December 31, 1969
Weeks after finalizing payment rates and policy changes affecting Medicare services furnished in hospital outpatient and Ambulatory Surgical Center ASC settings for calendar year CY 2022 the Centers f... [ Read More ]
Our provider is a PCP but also specializes in Pulmonary. The doctor goes to the hospital and reads PFT's - we have been coding as follows: 94726, 94060 (with bronchodilator) or 94010 (without bronchod... [ Read More ]
Can someone please advise on the correct usage of a possible use modifier 59? I work at family practice and billed an encounter as follows: This patient had a Kenolog injection as well as Bupivacaine... [ Read More ]
Z51.11 and Z51.12 are used for an encounter for administration of chemotherapy or immunotherapy. What is used when a patient presents for hormone therapy injection that is being used as chemotherapy? ... [ Read More ]
Initial surgery was 27829 with placement of two syndesmotic screws as fixation. Four months later, the fixation must be removed, and a permanent fixation put in place of the screws. I know, the 20680,... [ Read More ]
Hello ENT coders: A curved suction was passed into the left frontal sinus. Additionally, polyps in the right superior meatus are removed with microdebrider and are followed into the right sphenoid si... [ Read More ]
"Distal Coplaning and with Subacromial Decompression" for treatment of Impingement Syndrome Summary of Procedures: Soft tissue was used to skeletonize the undersurface of the acromion 4... [ Read More ]
Please help. 1. I work at a clinic that has a moderate complexity CLIA approved in house lab. I am a bit confused by the QW modifier. Do we still need to use the QW on Flu and strep swabs and urinal... [ Read More ]
I have a op note that I am trying to figure out how to code, this patient had a ganglion removed and we billed that as 28090 but with the recurrent one my coworker doesn't think that same code works t... [ Read More ]
The physician performed a gastric perforation repair (CPT 43840) and a colocutaneous fistula repair (44640-- slightly higher physician payment). (this was done endoscopically, so I'll use unlisted cod... [ Read More ]
Is there any information regarding a reduction of payment to a provider if a psychiatric code is billed with an office visit? Example: 99214 and 90833 Also Is there any information regarding a reduc... [ Read More ]